SMMT Insider Trading
Insider Ownership Percentage: 88.30%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Summit Therapeutics Insider Trading History Chart
This chart shows the insider buying and selling history at Summit Therapeutics by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Summit Therapeutics Share Price & Price History
Current Price: $20.32
Price Change: ▼ Price Decrease of -0.28 (-1.36%)
As of 03/28/2025 05:00 PM ET
Summit Therapeutics Insider Trading History
Summit Therapeutics Institutional Trading History
Data available starting January 2016
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.
Read More on Summit Therapeutics
Today's Range
Now: $20.32
52 Week Range
Now: $20.32
Volume
1,685,854 shs
Average Volume
3,430,026 shs
Market Capitalization
$14.99 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of Summit Therapeutics?
Who are the major institutional investors of Summit Therapeutics?
Which major investors are selling Summit Therapeutics stock?
During the previous quarter, SMMT stock was sold by these institutional investors:
- Citadel Advisors LLC
- Susquehanna International Group LLP
- FMR LLC
- Group One Trading LLC
- Wolverine Trading LLC
- GTS Securities LLC
- Jane Street Group LLC
- Handelsbanken Fonder AB
Which major investors are buying Summit Therapeutics stock?
In the previous quarter, SMMT stock was purchased by institutional investors including:
- Price T Rowe Associates Inc. MD
- Vanguard Group Inc.
- Pictet Asset Management Holding SA
- BNP Paribas Financial Markets
- Invesco Ltd.
- Twin Tree Management LP
- Boxer Capital Management LLC
- Polymer Capital Management HK LTD
Within the last year, these company insiders have bought Summit Therapeutics stock:
- Manmeet Singh Soni (COO)
- Mahkam Zanganeh (CEO)
- Ankur Dhingra (CFO)
Learn More investors buying Summit Therapeutics stock.